Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C35H31N6O4.Na |
| Molecular Weight | 622.6482 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC1=NC2=CN=CC=C2N1CC3CCN(CC3)C(=O)\C=C(\C4=CC=CC=C4)C5=CC=C(C=C5)\N=N\C6=CC(C([O-])=O)=C(O)C=C6
InChI
InChIKey=YLEYSRAGECECMB-UUHDFEAYSA-M
InChI=1S/C35H32N6O4.Na/c1-23-37-31-21-36-16-13-32(31)41(23)22-24-14-17-40(18-15-24)34(43)20-29(25-5-3-2-4-6-25)26-7-9-27(10-8-26)38-39-28-11-12-33(42)30(19-28)35(44)45;/h2-13,16,19-21,24,42H,14-15,17-18,22H2,1H3,(H,44,45);/q;+1/p-1/b29-20-,39-38+;
Dersalazine is a locally-acting compound. It is a potent platelet activating factor (PAF)-antagonist. Dersalazine inhibited IL-1beta or TNF-alpha production in THP-1 or U937 cells, respectively. Dersalazine sodium reduced colonic proinflammatory cytokines IL-1b, IL-6, and IL-17 in dextran sodium sulphate (DSS)–induced colitis. After oral administration, dersalazine sodium is mostly unabsorbed until it reaches the large bowel where the azo bond is reduced by bacteria releasing the active compound. Dersalazine had been in phase I clinical trial for the treatment of ulcerative colitis. No serious adverse reactions were detected in clinical trial. However, no recent development has been reported.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
57331752
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY | |||
|
BAB844203H
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY | |||
|
DBSALT002003
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY | |||
|
367249-56-7
Created by
admin on Mon Mar 31 20:56:53 GMT 2025 , Edited by admin on Mon Mar 31 20:56:53 GMT 2025
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
